1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Targeting RNA in Disease with Novel Technologies (TRDNT) is sponsored by NIH Common Fund. TRDNT supports short-term projects with significant impact in RNA-targeting therapies. This initiative aims to create new RNA-targeting treatments for diseases, including infectious diseases, and expand the 'druggable space' for conditions with few or no effective treatments.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
A **. gov** website belongs to an official government organization in the United States.
* National Institutes of Health * Division of Program Coordination Planning and Strategic Initiatives (DPCPSI) Search the Common Fund Website test * Acute To Chronic Pain Signatures (A2CPS)") * Bridge to Artificial Intelligence (Bridge2AI)") * Cellular Senescence Network (SenNet)") * Common Fund Data Ecosystem (CFDE)") * Complement Animal Research In Experimentation (Complement-ARIE)") * Gabriella Miller Kids First Pediatric Research Program (Kids First)") * Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa)") * High-Risk, High-Reward Research (HRHR)") * The Human BioMolecular Atlas Program (HuBMAP)") * Molecular Transducers of Physical Activity in Humans (MoTrPAC)") * Nutrition for Precision Health, powered by the All of Us Research Program * Precision Medicine with AI (PRIMED-AI)") * Replication to Enhance Research Impact Initiative * Somatic Cell Genome Editing (SCGE)") * Somatic Mosaicism Across Human Tissues (SMaHT)") * Stimulating Peripheral Activity to Relieve Conditions (SPARC)") * Transformative High Resolution Cryo-Electron Microscopy (CryoEM)") * Transformative Research to Address Health Disparities (THD) * Advancing Health Communication Science and Practice * Big Data to Knowledge (BD2K)") * Bioinformatics and Computational Biology * Bridging Interventional Development Gaps (BrIDGs)") * Building Blocks, Biological Pathways and Networks (BBPN)") * Community Partnerships to Advance Science for Society (ComPASS)") * Clinical Research Policy Analysis and Coordination (CRpac)") * Clinical and Translational Science Awards (CTSAs)") * Extracellular RNA Communication (ExRNA)") * Faculty Institutional Recruitment for Sustainable Transformation (FIRST)") * Genotype-Tissue Expression (GTEx)") * Healthcare Systems Research (HCS) Collaboratory Collaboratory") * Human Microbiome Project (HMP)") * Illuminating the Druggable Genome (IDG)") * Interdisciplinary Research (IR)") * Knockout Mouse Phenotyping Program (KOMP2)") * Library of Integrated Network-based Cellular Signatures (LINCS)") * Molecular Libraries and Imaging * National Electronics Clinical Trials and Research (NECTAR)") * New Models of Data Stewardship (NMDS)") * NIH Medical Research Scholars Program (MRSP)") * Patient-Reported Outcomes Measurement Information System (PROMIS)") * Protein Capture Reagents Program (PCRP)") * Regenerative Medicine Program (RMP)") * Science of Behavior Change (SOBC)") * Single Cell Analysis Program (SCAP)") * Strengthening the Biomedical Research Workforce * Undiagnosed Diseases Network (UDN)") * Sex As a Biological Variable * News & MediaRecent News & Videos Science Highlights News & Announcements Archives Videos Accessible Videos * New Program PlanningPlanning Process Planning Updates Criteria Reports * Evaluation & AssessmentEvaluation Report Library Presentations BEST Data * About UsWho We Are & What We Do History Congressional Budget Requests Office of Strategic Coordination Contacts Careers Internships with Common Fund Programs What is the Venture Program?
Watch the Video ## What is the NIH Common Fund Venture Program? This video provides an overview of the Common Fund Venture Program and how Venture Program initiatives are special. 3.
Targeting RNA In Disease With Novel Technologies (TRDNT) * Oculomics News & Announcements * SysBio News & Announcements * NIOI News & Announcements * NBSxWGS (BRIDGES-NBS) News & Announcements * Frequently Asked Questions * Frequently Asked Questions * Frequently Asked Questions * Frequently Asked Questions * Frequently Asked Questions ## Targeting RNA in Disease with Novel Technologies **Targeting RNA in Disease with Novel Technologies (TRDNT)**is the latest initiative from the NIH’s Common Fund’s Venture Program, which supports short-term projects with significant impact.
RNA-targeting therapies have the potential to treat diseases that have no, or few, effective treatments, and could be life-changing medications for patients suffering from these conditions. Including RNA as a target for treatment could have an enormous impact on the number of treatments and the number of diseases that can be treated.
RNAs have been linked to many diseases, including rare diseases like myotonic dystrophy, neurological disorders like Parkinson’s disease, certain aggressive forms of cancer, such as triple negative breast cancer, and heart failure, among others. Expanding research to target specific RNA molecules could have an enormous impact on how we prevent or treat many diseases that currently have few or no treatment options.
If RNA is targeted, it is estimated that the druggable space could be expanded 3-10-fold. This initiative will create new RNA-targeting treatments for the American people and will result in publicly shared and/or commercially sold products for the benefit of the American public.
**Targeting RNA in Disease with Novel Technologies (TRDNT) Challenge** The TRDNT Challenge has been published on theNIH Challenge site and will be open August 26, 2026. Interested in entering? Check out the FedTech webpage, the official registration and submission site for the TRDNT challenge.
**Missed the (TRDNT) Challenge Informational Webinar? Check out the webinar slides! ** The TRDNT Challenge held a Pre-Application Webinar for all interested prospective participants on Monday March 2, 2026, from 2:00-3:00 PM ET.
Review the slides**here**. On September 12th, 2025 the NIH Council of Councils approved the concept of the NIH Common Fund's Venture Program. Find out more by reviewing the Venture Venture Program description.
Or watch the videocast. This page last reviewed on August 12, 2026 * Evaluation & Assessment * Frequently Asked Questions * Freedom of Information Act NIH... Turning Discovery Into Health ® National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892 U.S. Department of Health and Human Services
According to the current listing, eligibility includes: Researchers focused on advancing understanding of RNA biology and developing RNA-based technologies. Confirm the full requirements in the official notice before applying.
Targeting RNA in Disease with Novel Technologies (TRDNT) is funded by NIH Common Fund. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
NOT-RM-26-004 asks the public for NIH-wide research challenges worth a 10-year, cross-institute program. There is no budget, no biosketch, no page limit, and no award. What there is: the five criteria every Common Fund investment has met since 2006, a new bullet about small-lab burden, and a fund whose FY 2026 request came in at $347.4 million — down 49.3 percent.
Read articleThe NIH Common Fund launched PRIMED-AI — Precision Medicine with AI: Integrating Imaging with Multimodal Data — as five coordinated funding opportunities (RFA-RM-27-011 through -015) that build a full pipeline from standards to clinic. Here is how the Playbook, Data-to-Model partnerships, Model-to-Clinic translation, Validation Center, and Logistics Center fit together, what each pays, who is eligible, and how to position before the October 2026 deadlines.
Read articleAvoid common NIH grant proposal mistakes including vague specific aims, weak methodology, and poor budget justification that lead to rejection.
Read article